- IN₹119.06bn
- IN₹125.61bn
- IN₹16.85bn
- 89
- 17
- 64
- 61
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 26.14 | ||
| PEG Ratio (f) | 2.77 | ||
| EPS Growth (f) | 10.41% | ||
| Dividend Yield (f) | 0.96% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.94 | ||
| Price to Tang. Book | 46.49 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 6.4 | ||
| EV to EBITDA | 19.47 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 14.25% | ||
| Return on Equity | 17.41% | ||
| Operating Margin | 25.87% | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 9,821.61 | 10,740.59 | 12,118.63 | 13,470.43 | 16,851.49 | 19,739.41 | 26,463.69 | 14.52% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -1.12 | +3.25 | +19.68 | +15.42 | -6.52 | +7.52 | +10.41 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Eris Lifesciences Limited is an India-based company that is primarily engaged in the manufacturing and marketing of pharmaceutical products. The Company’s manufacturing plant is located in Guwahati, Assam. Its therapeutic areas include oral diabetes care, cardiac care, pain/analgesics, gynecology, gastrointestinal, central nervous system (CNS), and vitamins, minerals, and nutrients (VMN). The Company's brands include Advog 0.2, Atorsave Gold 10, Baga NT 100, Calshine 60K Tablet, Carpela, Cilentra Plus 5, Cognix, D1000cal, Enoxsave 60, Glimisave M 4 forte, Levroxa 1000, Mac Rabonik Plus, Glimisave, Eritel, Renerve, Tendia, Olmin, Rabonik, Tayo, Cyblex, Lnbloc, Remylin, Zomelis, Crevast, Atorsave, Ginkocer and Metital. The Company’s wholly owned subsidiaries include Kinedex Healthcare Private Limited, Aprica Healthcare Limited, and Eris Healthcare Private Limited.
Directors
- Amit Bakshi CHM (42)
- Sachin Shah CFO (37)
- Milind Talegaonkar CCO (41)
- Inderjeet Negi EDR (45)
- Rajendrakumar Patel OTH (39)
- Kaushal Shah DRC (37)
- Krishnakumar Vaidyanathan DRC
- Sanjiv Kaul NED (59)
- Prashant Gupta IND
- Vijaya Sampath IND (68)
- Rajeev Dalal NID
- Kalpana Unadkat NID
- Last Annual
- March 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 25th, 2007
- Public Since
- June 29th, 2017
- No. of Shareholders
- 46,403
- No. of Employees
- 3,548
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
National Stock Exchange of India- Shares in Issue
- 136,047,466
- Address
- 7th Floor, Commerce House IV,,, AHMEDABAD, 380054
- Web
- https://eris.co.in/
- Phone
- +91 7969661000
- Auditors
- Deloitte Haskins & Sells LLP
Upcoming Events for ERIS
Q1 2025 Eris Lifesciences Ltd Earnings Release
Eris Lifesciences Ltd Annual Shareholders Meeting
Similar to ERIS
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the Eris Lifesciences share price?
As of Today at 19:08 UTC, shares in Eris Lifesciences are trading at IN₹875.10. This share price information is delayed by 15 minutes.
How has the Eris Lifesciences share price performed this year?
Shares in Eris Lifesciences last closed at IN₹875.10 and the price had moved by +41.32% over the past 365 days. In terms of relative price strength the Eris Lifesciences share price has outperformed the S&P BSE 100 Index by +9.61% over the past year.
What are the analyst and broker recommendations for Eris Lifesciences?
The overall consensus recommendation for Eris Lifesciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Eris Lifesciences dividend yield?
Eris Lifesciences does not currently pay a dividend.
Does Eris Lifesciences pay a dividend?
Eris Lifesciences does not currently pay a dividend.
When does Eris Lifesciences next pay dividends?
Eris Lifesciences does not currently pay a dividend.
How do I buy Eris Lifesciences shares?
To buy shares in Eris Lifesciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Eris Lifesciences?
As of the previous close price of IN₹875.10, shares in Eris Lifesciences had a market capitalisation of IN₹119.06bn.
Where are Eris Lifesciences shares listed?
Here are the trading details for Eris Lifesciences:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: ERIS
What kind of share is Eris Lifesciences?
Based on an overall assessment of its quality, value and momentum Eris Lifesciences is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Eris Lifesciences share price forecast for 2024?
The analyst consensus target price for shares in Eris Lifesciences is IN₹1,060.70. That is 21.21% above the last closing price of IN₹875.10.
Analysts covering Eris Lifesciences currently have a consensus Earnings Per Share (EPS) forecast of IN₹30.32 for the next financial year.
What is the trend in the Eris Lifesciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Eris Lifesciences. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -14.19%.
As of the last closing price of IN₹875.10, shares in Eris Lifesciences were trading +2.38% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Eris Lifesciences PE Ratio?
The Eris Lifesciences PE ratio based on its reported earnings over the past 12 months is 26.14. The shares last closed at IN₹875.10.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Eris Lifesciences?
Eris Lifesciences' management team is headed by:
- Amit Bakshi - CHM
- Sachin Shah - CFO
- Milind Talegaonkar - CCO
- Inderjeet Negi - EDR
- Rajendrakumar Patel - OTH
- Kaushal Shah - DRC
- Krishnakumar Vaidyanathan - DRC
- Sanjiv Kaul - NED
- Prashant Gupta - IND
- Vijaya Sampath - IND
- Rajeev Dalal - NID
- Kalpana Unadkat - NID